The Effect of Ablation Therapy on Barrett's Esophagus

N/AEnrolling By InvitationNCT00587314

Mayo Clinic600 enrolled

Overview

To assess the effect of ablative therapy (Photodynamic Therapy or Radiofrequency ablation ) on Barrett's Esophagus

To assess the effect of ablation therapy on Barrett's esophagus. Proposal Ablation therapy is an FDA approved treatment to decrease cancer risk in Barrett's esophagus mucosa. This is being performed in our Barrett's Esophagus Unit on a regular basis. However, the longterm outcomes of this therapy is not established and there are patients who have been treated who later re-develop Barrett's mucosa. This study will allow us store tissue samples that can later be used to assess the effect of ablative therapy on Barrett's esophagus.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Barrett's Esophagus Early Esophageal Adenocarcinoma

Interventions

BiopsyOTHER

Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have had or qualify for ablation therapy for treatment of their barrett's esophagus with high grade dysplasia or early esophageal adenocarcinoma * Ability to provide informed consent Exclusion Criteria: * Eastern Cooperative Oncology Group performance status 3 or 4 * Inability to tolerate endoscopic procedures * Pregnancy: Females of child-bearing age will be screened with pregnancy test.

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Response to treatment

presence of persistent or recurrence of barrett's esophagus and/or dysplasia

Time frame: at time of surveillance intervals

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.